Research and Development for Clinical Studies in the Blueprint MedTech (BPMT) Initiative
Contact and place of performance
Scott Duernberger
Not specified
Please see RFP_75N95022R00050 attached.
The National Institutes of Health, specifically the National Institute on Drug Abuse, is soliciting proposals for research and development services to support clinical studies within the Blueprint MedTech (BPMT) Initiative. This requirement, issued under solicitation number 75N95022R00050, is classified under NAICS 541715 for Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). The procurement is also identified by PSC AN11 for HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH.
The scope of work involves providing research and development for clinical studies as specified in the provided solicitation documents. Proposals are due by August 15, 2022. The formal notice includes three attachments: the final RFP posted on June 15, 2022, Amendment 1 posted on June 16, 2022, and Amendment 2 posted on July 19, 2022. Scott Duernberger is the point of contact for this requirement.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.